Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 13, Number 3—March 2007

Letter

gyrA Mutations in Fluoroquinolone-resistant Clostridium difficile PCR-027

Denise Drudy*Comments to Author , Lorraine Kyne†, Rebecca O’Mahony*, and Séamus Fanning*
Author affiliations: *University College Dublin, Dublin, Ireland; †Mater Misericordiae University Hospital, Dublin, Ireland;

Main Article

Table

Characterization of representative isolates, Ireland, 2006

Isolate Toxigenic status Ribotype Fluoroquinolone MIC μg/mL
Amino acid substitution
Ciprofloxacin Ofloxacin Levofloxacin Gatifloxacin Moxifloxacin
1470* A-B+ 017 >32 >32 3 0.38 0.25 Thr 82
VPI10463* A+B+ D >32 >32 3 0.38 0.25 Thr 82
CD 196* A+B+ 027 >32 >32 3 0.38 0.25 Thr 82
M216† A+B+ 027 >32 >32 >32 >32 >32 Thr-82-Iso
C2191† A+B+ 027 >32 >32 >32 >32 >32 Thr-82-Iso
V6-13† A+B+ 027 >32 >32 >32 >32 >32 Thr-82-Iso
V6-15† A+B+ 027 >32 >32 >32 >32 >32 Thr-82-Iso
V6-20† A+B+ 027 >32 >32 >32 >32 >3 Thr-82-Iso

*Control isolates VPI-10463, 1470 CD196.
†Clinical 027 isolates from 3 different institutions investigated in this study.

Main Article

Top of Page

USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO